EC
TVTX icon

EcoR1 Capital’s Travere Therapeutics TVTX Stock Holding History

EcoR1 Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,225,084
Closed -$21.8M – 36
2016
Q2 		$21.8M Hold
1,225,084
– – 8.6% 3
2016
Q1 		$16.7M Buy
1,225,084
+700
+0.1% +$10.6K 5.85% 6
2015
Q4 		$23.6M Buy
1,224,384
+216,724
+22% +$4.33M 7.42% 4
2015
Q3 		$20.4M Buy
1,007,660
+666,010
+195% +$19.7M 9.29% 4
2015
Q2 		$11.3M Sell
341,650
-68,350
-17% -$1.87M 3.78% 9
2015
Q1 		$9.82M Buy
+410,000
New +$6.25M 3.27% 12

Other funds holding TVTX

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EcoR1 Capital's TVTX Position: Q3 2016 in Review

EcoR1 Capital sold out of Travere Therapeutics (TVTX) in Q3 2016, closing a stake of 1,225,084 shares — an estimated $21.8M sold.

EcoR1 Capital first reported a position in TVTX in Q1 2015 and held it in 6 quarters. The position peaked at $23.6M in Q4 2015. 126 funds tracked by Wall St. Rank hold TVTX as of Q3 2016.

  • EcoR1 Capital reported no remaining Travere Therapeutics position as of Q3 2016 after selling out during the quarter.
  • EcoR1 Capital sold 1,225,084 Travere Therapeutics shares in Q3 2016, an estimated $21.8M.
  • EcoR1 Capital first reported a position in Travere Therapeutics in Q1 2015 and held it in 6 quarters.
  • EcoR1 Capital's Travere Therapeutics position peaked at $23.6M in Q4 2015.
  • 126 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2016.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.